Gold bars to be exempt from tariffs, White House clarifies
On June 27, 2025, Bios 2024 Co-Invest, LP, a director and 10% owner of Actuate Therapeutics , Inc. (NASDAQ:ACTU), purchased 71,428 shares of common stock at $7.0, for a total value of $499,996. The purchase comes as the stock has declined over 15% in the past week, with InvestingPro data showing the shares currently trading at $6.32. Following the transaction, Bios 2024 Co-Invest, LP directly holds 196,428 shares of Actuate Therapeutics.
The purchase was made pursuant to a Securities Purchase Agreement, where Bios 2024 Co-Invest also acquired warrants to purchase 71,428 shares of Actuate Therapeutics’ common stock. These warrants are exercisable at $7 and expire 20 days after the earlier of either the FDA issuing Breakthrough Therapy designation for elraglusib or the FDA providing written communication about the possibility of pursuing registration for elraglusib using Phase 2 or Phase 3 clinical data.
In other recent news, Actuate Therapeutics has reported significant findings regarding its investigational drug elraglusib in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The Phase 2 trial results revealed a statistically significant improvement in overall survival for patients treated with elraglusib in combination with gemcitabine/nab-paclitaxel, compared to the chemotherapy regimen alone. These promising results mark a potential shift in the standard of care for this challenging cancer type. Actuate plans to engage with U.S. and EU regulators to discuss the drug’s advancement toward a New Drug Application. Additionally, the company has identified several biomarkers that may help predict which patients could benefit most from elraglusib, supporting the use of non-invasive blood-based markers in future trials. In another development, Craig-Hallum has initiated coverage of Actuate Therapeutics with a Buy rating and set a price target of $21. The firm expressed optimism about the drug’s potential to improve survival outcomes in mPDAC. Actuate’s financial position, with $8.6 million in cash, could be bolstered by these positive clinical trial developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.